Laboratory of Veterinary Pathology, Division of Animal Life Science, Institute of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan; Cooperative Division of Veterinary Sciences, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan.
Laboratory of Veterinary Pathology, College of Veterinary Medicine, Southwest University, No. 2 Tiansheng Road, BeiBei District, Chongqing, 400715, PR China.
Food Chem Toxicol. 2024 Mar;185:114486. doi: 10.1016/j.fct.2024.114486. Epub 2024 Feb 1.
Ochratoxin A (OTA) is a renal carcinogen in rats, and repeated administration induces karyomegaly in proximal tubular epithelial cells (PTECs) of the outer stripe of the outer medulla (OSOM) before inducing proliferative lesions. To investigate whether OTA induces micronuclei (MN) in PTECs, we performed an in vitro MN assay using rat renal NRK-52E PTECs after treatment for ≤21 days, and an in vivo OSOM MN assay in rats treated with OTA, other renal carcinogens, or non-carcinogenic renal toxicants for 4 or 13 weeks. The in vitro assay revealed an increased frequency of micronucleated cells from the acceptable dose level for cell viability, even after 21 days of treatment. The in vivo assay also revealed a dose- and treatment period-dependent increase in PTECs with γ-H2AX MN. OTA-specific gene expression profiling by OSOM RNA sequencing after week 13 revealed the altered expression of genes related to microtubule-kinetochore binding, the kinesin superfamily, centriole assembly, DNA damage repair, and cell cycle regulation. MN formation was also observed with other renal carcinogens that induce karyomegaly similarly to OTA. These results imply that γ-H2AX MN formation by OTA treatment is related to the induction of chromosomal instability accompanying karyomegaly formation before proliferative lesions form, providing a new insight into the carcinogenic mechanism that may be relevant to humans.
赭曲霉毒素 A(OTA)是一种大鼠肾脏致癌物质,在诱导增殖病变之前,重复给药会在外髓外层的近端肾小管上皮细胞(PTEC)中诱导巨细胞形成。为了研究 OTA 是否会在 PTEC 中诱导微核(MN),我们使用大鼠肾 NRK-52E PTEC 进行了体外 MN 测定,在 ≤21 天的治疗后进行,并且在大鼠中进行了体内 OSOM MN 测定用 OTA、其他肾脏致癌物质或非致癌性肾脏毒物处理 4 或 13 周。体外测定显示,即使在 21 天的治疗后,从可接受的细胞活力剂量水平开始,微核细胞的频率也增加。体内测定还显示,PTEC 中 γ-H2AX MN 的频率与剂量和治疗时间有关。在第 13 周用 OSOM RNA 测序进行的 OTA 特异性基因表达谱分析显示,与微管-动粒结合、驱动蛋白超家族、中心粒组装、DNA 损伤修复和细胞周期调节相关的基因表达发生改变。其他具有与 OTA 相似的诱导巨细胞形成能力的肾脏致癌物质也可诱导 MN 形成。这些结果表明,OTA 处理引起的 γ-H2AX MN 形成与增殖病变形成之前伴随巨细胞形成的染色体不稳定性的诱导有关,为可能与人类相关的致癌机制提供了新的见解。